BiotechTube

Tirzepatide + Semaglutide

Pre-clinicalWithdrawn
1 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolic Health

Conditions

Metabolic Health

Trial Timeline

Jul 1, 2023 → Jul 1, 2023

NCT ID
NCT06354101

About Tirzepatide + Semaglutide

Tirzepatide + Semaglutide is a pre-clinical stage product being developed by Eli Lilly for Metabolic Health. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06354101. Target conditions include Metabolic Health.

What happened to similar drugs?

19 of 20 similar drugs in Metabolic Health were approved

Approved (19) Terminated (4) Active (1)
✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
✅Metformin + PlaceboEli LillyApproved
✅Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
✅Rosuvastatin + AtorvastatinAstraZenecaApproved
✅rosuvastatinAstraZenecaApproved
✅Simvastatin + Simvastatin/EzetimibeMerckApproved
✅Simvastatin + Vytorin + Placebo + EzetimibeMerckApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06354101Pre-clinicalWithdrawn
NCT05822830Phase 3Completed
NCT03987919Phase 3Completed

Competing Products

20 competing products in Metabolic Health

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
35
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
40
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
40
14C-labeled YM178Astellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
LY518674Eli LillyPhase 2
35
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
47
Metformin + PlaceboEli LillyApproved
43
LY3849891 + PlaceboEli LillyPhase 1
33
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
50
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaApproved
43
AZD2693 + PlaceboAstraZenecaPhase 1
29
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40
rosuvastatinAstraZenecaApproved
43
EfinopegdutideMerckPhase 2
35
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
27
Vericiguat + PlaceboMerckPhase 2
35
MetforminMerckPhase 2
35